Drug intelligence / Profile preview

Trp-CA

Development stage: Preclinical
Modality: Small Molecules

Overview

Trp-CA, also known as tryptophan-cholic acid, is a microbial amino-acid-conjugated bile acid. It has been identified as significantly decreased in patients with type 2 diabetes (T2D), and its abundance is negatively correlated with clinical glycemic markers. Research indicates that Trp-CA improves glucose tolerance in diabetic mice. Its mechanism of action involves acting as a ligand for the orphan G protein-coupled receptor (GPCR) Mas-related G protein-coupled receptor family member E (MRGPRE), activating both MRGPRE-Gs-cyclic AMP and MRGPRE-β-arrestin-1-aldolase A signaling pathways. The bacterial bile salt hydrolase/transferase of Bifidobacterium is responsible for its production.

Other names: tryptophan-cholic acid

Targets

MRGPRE (Mas-related G protein-coupled receptor member E)

Beyond the preview

Go deeper on Trp-CA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trp-CA.

Explore the full profile